News
2d
Zacks.com on MSNABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering ...
AbbVie and Roche's Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) that was supposed to confirm its efficacy.
Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic ...
6d
MedPage Today on MSNTime-Limited or Indefinite Therapy in CLLTime-limited (or fixed-duration) therapy offers a treatment-free interval, potentially leading to improved quality of life and reduced long-term toxicities. However, it may be less effective for ...
Here are some of the highest stock prices in history. The reasons behind these stock prices can vary but understanding them can lead to better investing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results